Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Viking Therapeutics, Inc. (VKTX)

27.28 +0.42 (+1.56%)
At close: October 30 at 4:00:01 PM EDT
27.04 -0.24 (-0.88%)
After hours: October 30 at 7:28:02 PM EDT
Trade VKTX on Coinbase
Chart Range Bar
Loading chart for VKTX

What's happening with VKTX?

39m ago
Powered by Yahoo Scout

Viking Therapeutics reported a wider third-quarter loss as it expanded late-stage obesity-drug trials. Its lead candidate, VK2735, is advancing through injectable and oral Phase 3 programs, while the company ended the quarter with approximately $960 million in cash and investments. Broker ratings remain favorable, but commercialization is still roughly 2.5 years awayand clinical, regulatory, dilution, and valuation risks remain.

Powered by Yahoo Scout
  • Previous Close 26.86
  • Open 26.69
  • Bid 25.80 x 100
  • Ask 28.37 x 100
  • Day's Range 26.31 - 27.83
  • 52 Week Range 23.82 - 43.15
  • Volume 5,085,875
  • Avg. Volume 4,740,859
  • Market Cap (intraday) 3.479B
  • Beta (5Y Monthly) 0.65
  • PE Ratio (TTM) --
  • EPS (TTM) -5.42
  • Earnings Date Oct 28, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 95.32
  • Zacks Rating Bullish

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

www.vikingtherapeutics.com

53

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VKTX
22.46%
S&P 500 (^GSPC)
10.73%

1-Year Return

VKTX
28.53%
S&P 500 (^GSPC)
11.11%

3-Year Return

VKTX
184.76%
S&P 500 (^GSPC)
81.91%

5-Year Return

VKTX
368.73%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue --
Earnings -183.19M
Profit Margin 0.00%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-150M
-100M
-50M
0
0.0%

Analyst Insights

View More

Top Analyst

Truist Securities
66/100
Latest Rating
Buy

Analyst Price Targets

34.00
95.32 Average
27.28 Current
125.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/20/2026
Analyst Canaccord Genuity
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 114 -> 106

Statistics

View More

Valuation Measures

Annual
As of 10/29/2026
  • Market Cap

    3.43B

  • Enterprise Value

    2.72B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    5.82

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -47.23%

  • Return on Equity (ttm)

    -96.37%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -627.2M

  • Diluted EPS (ttm)

    -5.42

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    959.81M

  • Total Debt/Equity (mrq)

    43.27%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

27.28 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 07/30/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 01/06/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 10/29/2025

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 07/07/2025

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: